Novartis has faced a series of high-profile clinical setbacks, reigniting a familiar question across the industry: are these isolated disappointments or symptoms of a broader challenge in pharma innovation?
AI’s rapid growth is no longer just a technology story – it is becoming an energy infrastructure test. The World Energy Council’s 2026 World Energy Trilemma